Previous 10 |
Imago BioSciences Inc. (NASDAQ:IMGO) traded at a new 52-week high today of $20.06. Approximately 121,000 shares have changed hands today, as compared to an average 30-day volume of 131,000 shares. Imago BioSciences Inc. (NASDAQ:IMGO) defies analysts with a current price ($18.81) 11.6% ab...
Imago BioSciences, Inc. (Imago) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that the European Medicines Agency (EMA) has granted orphan designation for bomedemstat, a l...
Imago BioSciences, Inc. (“Imago”) (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that in connection with its previously announced public offering of its common s...
Imago BioSciences, Inc. (“Imago”) (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the closing of $134.4 million in gross proceeds from its previously announced in...
News, Short Squeeze, Breakout and More Instantly...
Imago BioSciences Inc. Company Name:
IMGO Stock Symbol:
NASDAQ Market:
Imago BioSciences Inc. Website:
NEW YORK, NY / ACCESSWIRE / December 27, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Imago BioSciences, Inc. (NASDAQ: IMG...
NEW YORK, NY / ACCESSWIRE / December 23, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Lakeland Bancorp, Inc. (NASDAQ:LBAI)...